Rituximab
- PDF / 170,194 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 72 Downloads / 178 Views
1 S
Rituximab Drug resistance and transformation to other lymphomas: 8 case reports
In study of 252 patients (biopsied between 2000 and 2018), 8 patients [ages and sexes not stated] were described, who developed drug resistance with or without transformation to proliferation of plasmablastic/plasmacytoid tumour cells, CD20– diffuse large Bcell lymphoma (DLBCL), MALT lymphoma with marked plasmacytoid differentiation, classic Hodgkin lymphoma or CD20– anaplastic large cell lymphoma (ALCL)-like undifferentiated lymphoma following treatment with rituximab for CD20+ B-cell nonHodgkin lymphoma [rotes not stated]. The patients had CD20+ B-cell non-Hodgkin lymphoma (B-NHLs) in the form of chronic lymphocytic leukaemia (CLL), high-grade B-cell lymphoma (HGBL), lymphoplasmacytic lymphoma (LPL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL) or DLBCL. The patients were scheduled to receive rituximab [Zenyaku Kogyo] 375 mg/m2 once a week as monotherapy and once every cycle for the rituximab-containing chemotherapy. After rituximab therapy, B-NHLs relapse or refractory were noted. Biopsy of all patients showed CD20– changes, suggesting rituximab resistance. Two of these patients showed CD20– change without histological changes. In the remaining 6 patients, histopathological patterns related to CD20– change were noted, which were as follows: combined lymphoma in the form of CD20– DLBCL and MALT lymphoma with marked plasmacytoid differentiation (n=1), combined lymphoma in the form of classic Hodgkin lymphoma and CD20– DLBCL (n=1), CD20– anaplastic large cell lymphoma-like undifferentiated lymphoma (n=1), CD20– DLBCL (n=2) and transformation to proliferation of plasmablastic/plasmacytoid tumour cells (n=1). Maeshima AM, et al. Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy. Annals of Hematology 99: 2141-2148, No. 9, Sep 2020. Available from: URL: http://doi.org/10.1007/s00277-019-03853-1
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803501826
Reactions 19 Sep 2020 No. 1822
Data Loading...
